Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

Highlights

• Advantage of tetravalent conjugated vaccines over unconjugated vaccines.
• Expansion of meningococcal vaccination beyond the 11-21 years age group.
• Comparison of Menveo and Menactra tetravalent vaccines
• Serotype B vaccines Bexsero and Trumenba

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.